From November 1, 2010 to November 1, 2014, a total of 110 consecutive AF patients undergoing coronary stenting with CAD were retrospectively evaluated in the Cardiology Department, The First Affiliated Hospital of Dalian Medical University; and from October 1, 2014 to November 1, 2014, a total of 166 consecutive patients undergoing coronary stenting without AF were also collected and evaluated as the control.
The follow-up clinical reevaluation of patients was performed by telephone contact from December 1, 2015, to December 31, 2015, and the data including the use of antithrombotic therapy and adverse events were recorded and followed up for 12 months after coronary stenting. The primary end-point was composite of all-cause death, nonfatal recurrent myocardial infarction (MI), stroke, serious bleeding events, unplanned repeat revascularization, and worsening heart failure.
Event Rates 1 Year After Coronary Stenting
and Surgery C&BC PCI Outcome (n = 897) (n = 903) Death 3.5% 4.3% Nonfatal stroke 2.2% 0.6% * Nonfatal myocardial infarction 3.2% 4.8% Combined rate of death, stroke, and MI 7.7% 7.6% Repeat revascularization 5.9% 13.7% * Combined rate of death, stroke, MI, 12.1% 17.8% * undrepeat revascularization * Statistically significant difference between groups Source: Dr.
Does B-vitamin supplementation reduce the risk of restenosis after coronary stenting
A year earlier, in July 2006, about 86% of all coronary stenting
at the same hospitals used DES.
RELATED ARTICLE: Overuse of Coronary Stenting
The researchers assessed stent thrombosis in 1,000 patients (788 men, 212 women) who underwent percutaneous coronary stenting
between 1997 and 2001.
In 40 of the patients, the chemotherapy--primarily for lymphoma; leukemia; or breast, lung, ovarian, colon, or bladder cancer--was administered within 3-4 weeks of coronary stenting